Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 55 min ago
Peer-reviewedCC BY-NC-ND 4.0NPJ Precision Oncology

From tumor regression grading to interpretable endpoints in neoadjuvant oncology

  • Cédric Schraepen1
  • Albert Wolthuis1
  • Wentao Tang2
  • André D’Hoore1
  • Giuseppe Floris3
  • Allyson M. Peddle4
  • Xavier Sagaert3
  • Sara Verbandt4
  • Thomas McKee5
  • Inti Zlobec6
  • Jianmin Xu2
  • Sabine Tejpar4,7
1 more authors
  • Gertjan Rasschaert4,7
7 affiliations
  1. 1Abdominal Surgery Department, University Hospitals Leuven, Leuven, Belgium
  2. 2Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
  3. 3Department of Pathology, University Hospitals Leuven, Leuven, Belgium
  4. 4Laboratory for Digestive Oncology, KU Leuven, Leuven, Belgium
  5. 5Aurigen SA, Lausanne, Sonic Healthcare Ltd subsidiary, Lausanne, Switzerland
  6. 6Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
  7. 7Gastrointestinal Oncology Department, University Hospitals Leuven, Leuven, Belgium
Read full textPDFDOICite

Abstract

Neoadjuvant therapy is expanding rapidly across tumor types, yet efficacy endpoints remain anchored in subjective tumor regression grading systems developed for cytotoxic therapy. We argue that post-treatment histopathology should evolve toward quantitative and biologically interpretable metrics integrating tumor burden, immune contexture, and spatial organization. We outline a validation pathway distinguishing prognostic biomarkers from true surrogate endpoints and propose a tumor- and regimen-aware framework for developing reproducible histologic endpoints in neoadjuvant oncology.

Related

  1. Bayesian mediation multi-state model elucidates the impact of cancer immunity on multiple oncology endpoints after chemoradiotherapy for esophageal cancer
    Yiqing Chen, Jie Zhou, Peng Wei +7
    Scientific ReportsPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossref
  2. USFDA Oncology Drug Approvals from 2014- 2025: Comparing non-immunotherapy and immunotherapy approvals, their endpoints, and their efficacy.
    N. Bapodra, K. G. Morse, S. E. Bates +1
    medRxivPreprintCC BY-NDFull textOncologymedRxiv
  3. Bacterial Meningitis Following Robot-Assisted Radical Prostatectomy After Neoadjuvant Precision Oncology-Directed Therapy: A Case Report.
    Thomas Allen, Gabrielle R Yankelevich, Stephen J Savage +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. 3-D ordinal regression CNN for opportunistic breast density grading on chest CT.
    Artur Wysoczanski, Elsa D Angelini, Sachin R Jambawalikar +2
    Journal of translational medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCDOAJ
  5. Lymph Node Regression Improves Prognostic Stratification in Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Cohort Study.
    Jian Zheng, Wenbin Shen, Jianzhong Cao +13
    MedCommPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC

Cite

BibTeXRIS
BibTeX
@article{schraepen2026from,
  title = {{From tumor regression grading to interpretable endpoints in neoadjuvant oncology}},
  author = {Cédric Schraepen and Albert Wolthuis and Wentao Tang and André D’Hoore and Giuseppe Floris and Allyson M. Peddle and Xavier Sagaert and Sara Verbandt and Thomas McKee and Inti Zlobec and Jianmin Xu and Sabine Tejpar and Gertjan Rasschaert},
  journal = {NPJ Precision Oncology},
  year = {2026},
  month = jul,
  doi = {10.1038/s41698-026-01592-x},
  url = {https://doi.org/10.1038/s41698-026-01592-x},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - From tumor regression grading to interpretable endpoints in neoadjuvant oncology
AU  - Cédric Schraepen
AU  - Albert Wolthuis
AU  - Wentao Tang
AU  - André D’Hoore
AU  - Giuseppe Floris
AU  - Allyson M. Peddle
AU  - Xavier Sagaert
AU  - Sara Verbandt
AU  - Thomas McKee
AU  - Inti Zlobec
AU  - Jianmin Xu
AU  - Sabine Tejpar
AU  - Gertjan Rasschaert
PY  - 2026
DA  - 2026/07/03
JO  - NPJ Precision Oncology
DO  - 10.1038/s41698-026-01592-x
UR  - https://doi.org/10.1038/s41698-026-01592-x
AB  - Neoadjuvant therapy is expanding rapidly across tumor types, yet efficacy endpoints remain anchored in subjective tumor regression grading systems developed for cytotoxic therapy. We argue that post-treatment histopathology should evolve toward quantitative and biologically interpretable metrics integrating tumor burden, immune contexture, and spatial organization. We outline a validation pathway distinguishing prognostic biomarkers from true surrogate endpoints and propose a tumor- and regimen-aware framework for developing reproducible histologic endpoints in neoadjuvant oncology.
SN  - 2397-768X
ER  -